Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.13
- Piotroski Score 3.00
- Grade Buy
- Symbol (STOK)
- Company Stoke Therapeutics, Inc.
- Price $11.26
- Changes Percentage (-0.44%)
- Change -$0.05
- Day Low $11.13
- Day High $11.73
- Year High $17.58
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/05/2025
- Fiscal Year End N/A
- Average Stock Price Target $22.00
- High Stock Price Target $58.00
- Low Stock Price Target $18.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.42
- Trailing P/E Ratio -6.14
- Forward P/E Ratio -6.14
- P/E Growth -6.14
- Net Income $-104,699,000
Income Statement
Quarterly
Annual
Latest News of STOK
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Bram Stoker's Dracula: Francis Ford Coppola's very horny vampire epic
Francis Ford Coppola's return to cinema with Megalopolis brings to mind his earlier maximalist fable, Bram Stoker's Dracula, starring Gary Oldman as the Count. The film showcases Coppola's visionary s...
By The Guardian | 2 days ago -
Chocolate makers stoke boom for Indian cocoa beans
Dr. George Matthew's cocoa farming success in Kerala started after squirrels spread cocoa seeds across his farm, leading to healthy cocoa plants. Despite India's potential, it only contributes 1% of g...
By Yahoo! Finance | 3 days ago -
Revenge tour? Trump campaign rhetoric stokes fears about retribution-focused presidency
Democrats had warned of Trump's revengeful behavior if elected, citing his threats to prosecute opponents. Despite concerns, Trump's allies downplay retribution talk, emphasizing his focus on a succes...
By USA Today | 2 weeks ago
